Philippe Aftimos, MD [7505]

How are genomic alterations detected by massive parallel sequencing and NGS changing precision-focused cancer therapy; and how are trials adapting to NGS-based molecular targets? (English) Video

How are genomic alterations detected by massive parallel sequencing and NGS changing precision-focused cancer therapy; and how are trials adapting to NGS-based molecular targets? (English)

How are the genomic alterations that can be detected by massive parallel sequencing and NGS changing the landscape of precision-focused cancer therapy; and how are trial designs adapting to NGS-based molecular targets? (English)
Philippe Aftimos, MD

Philippe Aftimos, MD

What common mutations, alterations, and rearrangements--EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS1-- present in solid tumors represent the best molecular targets for cancer therapy? (English) Video

What common mutations, alterations, and rearrangements--EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS1-- present in solid tumors represent the best molecular targets for cancer therapy? (English)

What common mutations, alterations, and rearrangements—among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS1— present in solid tumors represent the best molecular targets for cancer therapy? What validations do we have that such aligning ...
Philippe Aftimos, MD

Philippe Aftimos, MD

What patients with cancer should get NGS? At what stage of their disease should they get this test? Where should the samples come from? What information do the results provide? (English) Video

What patients with cancer should get NGS? At what stage of their disease should they get this test? Where should the samples come from? What information do the results provide? (English)

What patients with cancer should get NGS? At what stage of their disease should they get this diagnostic test? Where should the samples come from? What do we do the results? What information do the results provide? Can you give us specific examples? (English)
Philippe Aftimos, MD

Philippe Aftimos, MD

What therapeutic strategy emerges if you detect multiple genomic alterations in a tumor, including mutations, through NGS? And what if subclones emerge? (English) Video

What therapeutic strategy emerges if you detect multiple genomic alterations in a tumor, including mutations, through NGS? And what if subclones emerge? (English)

What therapeutic strategy emerges if you detect multiple genomic alterations in a tumor, including mutations, through NGS? And what if subclones emerge? (English)
Philippe Aftimos, MD

Philippe Aftimos, MD

How does FoundationOne NGS comprehensive sequencing compare to "hot spot panels" for detecting actionable alterations? What are the limitations -- including false negatives -- of hot spot panels? (English) Video

How does FoundationOne NGS comprehensive sequencing compare to "hot spot panels" for detecting actionable alterations? What are the limitations -- including false negatives -- of hot spot panels? (English)

How does FoundationOne NGS comprehensive sequencing compare to common “hot spot panels” with respect to detecting clinically actionable alterations? How does FoundationOne, NGS-based technology differ from “hot spot” panels? What are the ...
Philippe Aftimos, MD

Philippe Aftimos, MD

How do you select patients with solid tumors for NGS? Is it just for patients with cancer at time of presentation? Patients under treatment? Assessment of tumors in patients who have relapsed? (English) Video

How do you select patients with solid tumors for NGS? Is it just for patients with cancer at time of presentation? Patients under treatment? Assessment of tumors in patients who have relapsed? (English)

How do you select patients with solid tumors that are appropriate for NGS? Is it useful just for patients with cancer at time of presentation? Can NGS be used for patients under treatment? For assessment of tumors in patients who have relapsed? (English)
Philippe Aftimos, MD

Philippe Aftimos, MD

Can you share examples of cancer patients -- including those with NSCLC, metastatic breast cancer, and colorectal cancer -- whose treatment was more precisely shaped by NGS reports? (English) Video

Can you share examples of cancer patients -- including those with NSCLC, metastatic breast cancer, and colorectal cancer -- whose treatment was more precisely shaped by NGS reports? (English)

Can you share examples of actual cancer patients — including those with NSCLC, metastatic breast cancer, and colorectal cancer — whose treatment was more precisely shaped by having access to NGS reports such as that provided by FoundationOne ...
Philippe Aftimos, MD

Philippe Aftimos, MD